JPRN-UMIN000006383尚未招募1 期
Phase I and dose-finding study of TS-1 with Abraxane for metastatic breast cancer - TS-1/ABI Phase I tudy
Tokusima University Hospital0 个研究点目标入组 12 人开始时间: 2011年9月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)male breast cancer 2)taboo to use TS-1 or Abraxane 3)had undergone treatment with TS-1 or Abraxane chemotherapy prior to this study 4)pregnant or nursing women or who like be pregnant.possible to pregnancy 5)with active double cancer 6)wiht severe complications 7)uncontrolled dropsy pleural effusion,abdominal dropsy 8)wiht brain metastasis 9)had a previos serious medical illness or allergy 10)doctor's decision not to be registered to this study
研究者
相似试验
已完成
1 期
Phase 1 study of TS-1 with Abraxane for metastatic breast cancermetastatic breast cancerJPRN-UMIN000016377kyoto prefectural university of medicine12
未知
1 期
A Phase I Study of TS-1 in Combination with ABI-007 every three weeks in Patients with Unresectable or Recurrent Gastric CancerJPRN-jRCT2080221526Taiho Pharmaceutical Co., Ltd.30
暂停
不适用
A phase I study of TS-1 and docetaxel for advanced gastric cancerJPRN-C000000188Department of Medical Oncology, Kinki University School of Medicine15
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with or without genetic abnormalitiesAdvanced solid tumors and multiple myelomaMedDRA version: 16.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2013-004810-16-ESTaiho Pharma USA, Inc.835
招募中
不适用
A PhaseII Study of Dose Schedule of TS-1 for Metastatic/Advanced Breast CancerMetastatic/Advanced Breast CancerJPRN-UMIN000008879Wakayama Medical University, Department of Thoracic and Cardiovascular Surgery40